| Advances in cancer immunotherapy 2019–latest trends S Kruger, M Ilmer, S Kobold, BL Cadilha, S Endres, S Ormanns, ... Journal of Experimental & Clinical Cancer Research 38, 1-11, 2019 | 591 | 2019 |
| Killing mechanisms of chimeric antigen receptor (CAR) T cells MR Benmebarek, CH Karches, BL Cadilha, S Lesch, S Endres, S Kobold International journal of molecular sciences 20 (6), 1283, 2019 | 495 | 2019 |
| CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment M Di Pilato, R Kfuri-Rubens, JN Pruessmann, AJ Ozga, M Messemaker, ... Cell 184 (17), 4512-4530. e22, 2021 | 322 | 2021 |
| Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis X Liu, J Li, BL Cadilha, A Markota, C Voigt, Z Huang, PP Lin, DD Wang, ... Science advances 5 (6), eaav4275, 2019 | 216 | 2019 |
| Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy M Di Pilato, EY Kim, BL Cadilha, JN Prüßmann, MN Nasrallah, ... Nature 570 (7759), 112-116, 2019 | 195 | 2019 |
| Limitations in the design of chimeric antigen receptors for cancer therapy S Stoiber, BL Cadilha, MR Benmebarek, S Lesch, S Endres, S Kobold Cells 8 (5), 472, 2019 | 179 | 2019 |
| T cells armed with CXC chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours S Lesch, V Blumenberg, S Stoiber, A Gottschlich, J Ogonek, BL Cadilha, ... Nature biomedical engineering 5 (11), 1246-1260, 2021 | 134 | 2021 |
| Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors BL Cadilha, MR Benmebarek, K Dorman, A Oner, T Lorenzini, H Obeck, ... Science advances 7 (24), eabi5781, 2021 | 93 | 2021 |
| Determinants of response and resistance to CAR T cell therapy S Lesch, MR Benmebarek, BL Cadilha, S Stoiber, M Subklewe, S Endres, ... Seminars in Cancer Biology 65, 80-90, 2020 | 81 | 2020 |
| Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia A Gottschlich, M Thomas, R Grünmeier, S Lesch, L Rohrbacher, V Igl, ... Nature biotechnology 41 (11), 1618-1632, 2023 | 50 | 2023 |
| High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy F Rataj, SJ Jacobi, S Stoiber, F Asang, J Ogonek, N Tokarew, BL Cadilha, ... British journal of cancer 120 (1), 79-87, 2019 | 49 | 2019 |
| T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis D Briukhovetska, J Suarez-Gosalvez, C Voigt, A Markota, AD Giannou, ... Immunity 56 (1), 143-161. e11, 2023 | 48 | 2023 |
| Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy CH Karches, MR Benmebarek, ML Schmidbauer, M Kurzay, R Klaus, ... Clinical Cancer Research 25 (19), 5890-5900, 2019 | 42 | 2019 |
| Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy A Prokopi, CH Tripp, B Tummers, F Hornsteiner, S Spoeck, JC Crawford, ... Journal for immunotherapy of cancer 9 (1), 2021 | 39 | 2021 |
| Microphthalmia-associated transcription factor (MITF) regulates immune cell migration into melanoma GM Wiedemann, C Aithal, A Kraechan, C Heise, BL Cadilha, J Zhang, ... Translational Oncology 12 (2), 350-360, 2019 | 39 | 2019 |
| PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-hodgkin lymphoma F Rataj, FBT Kraus, M Chaloupka, S Grassmann, C Heise, BL Cadilha, ... Frontiers in immunology 9, 1955, 2018 | 37 | 2018 |
| A modular and controllable T cell therapy platform for acute myeloid leukemia MR Benmebarek, BL Cadilha, M Herrmann, S Lesch, S Schmitt, S Stoiber, ... Leukemia 35 (8), 2243-2257, 2021 | 33 | 2021 |
| Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 A Darwich, A Silvestri, MR Benmebarek, J Mouriès, B Cadilha, ... Journal for Immunotherapy of Cancer 9 (11), 2021 | 25 | 2021 |
| Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins F Blaeschke, D Stenger, A Apfelbeck, BL Cadilha, MR Benmebarek, ... Blood Cancer Journal 11 (6), 108, 2021 | 24 | 2021 |
| Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function M Seifert, MR Benmebarek, D Briukhovetska, F Märkl, J Dörr, BL Cadilha, ... British Journal of Cancer 127 (12), 2175-2185, 2022 | 22 | 2022 |